Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet

NCT01694420 | Completed Phase 3 Results

• 2 other identifiers: Pro00035447IN-US-236-0124
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 2

Brief Summary

This is a multicenter, single arm, 48-week open-label study of FDC ELV/COBI/FTC/TDF \[Stribild\] in acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. Participants will be enrolled for 96 weeks. Clinical care and study drug (ELV/COBI/FTC/TDF) will be provided for the first 48 weeks. After week 48, clinical care but not study drug will be provided through week 96. A study participant suppressed at week 48 can continue on FDC ELV/COBI/FTC/TDF. The primary hypothesis is that once daily fixed-dose combination elvitegravir (ELV), cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) will rapidly reduce viral replication to \<50 copies RNA/ml in participants with acute HIV infection. The secondary hypotheses to be considered are 1) virologic response rates as measured by plasma HIV RNA levels will be non-inferior or superior to a historical group of participants from the PHI cohort treated with EFV/FTC/TDF, 2) compared to historical controls treated with EFV/FTC/TDF, plasma HIV RNA will decrease more rapidly in PHI participants treated with ELV/COBI/FTC/TDF, 3) compared to historical controls treated with EFV/FTC/TDF, immune activation as measured by the proportion CD4+ and CD8+ cells expressing HLA-DR and CD38+ will decrease more rapidly in PHI participants treated with ELV/COBI/FTC/TDF, 4)in a subset of participants samples will be obtained from compartments such as the gastrointestinal tract, and lymphoid tissues to assess changes over time in parameters such as HIV-1 RNA, immunologic responses to HIV, and tissue and anatomic reservoirs. We hypothesize that treatment with the ELV/COBI/FTC/TDF will demonstrate improved viral clearance in these compartments as compared to historical controls treated with EFV/FTC/TDF. 5) in a subset of participants who remain suppressed on therapy, resting CD4 cells with replication-competent HIV-1 (latent reservoir) will be quantitated and compared to similar measurements in PHI participants treated with EFV/FTC/TDF. In addition, we will compare these results to those measured in HIV-1 infected participants treated and 6) ELV/COBI/FTC/TDF will be well tolerated, and the proportion of participants who require treatment modification will be less than that observed in participants treated with EFV/FTC/TDF.

Conditions

HIV

Outcome Measures

Primary Outcomes (2)

• Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24

  24 weeks

• Virologic Efficacy of the Fixed Dose Combination (FDC) ELV/COBI/FTC/TDF Given Once Daily to Participants With Acute HIV Infection as Determined by the Proportion of Treated Participants With HIV-1 RNA to <50 Copies/mL at Week 48

  48 weeks

Secondary Outcomes (2)

• Immune Activation as Measured by the Proportion of CD4+ and CD8+ Cells Expressing HLA-DR and CD38+

  48 weeks

• Rate of Virologic Decline in the First 48 Weeks of Treatment Comparing FDC ELV/COBI/FTC/TDF to FDC EFV/FTC/TDF

  48 weeks

Other Outcomes (2)

• Number of Participants With Grade 3 or Grade 4 Adverse Events

  48 weeks

• Number of Participants With Adverse Events Related to Study Drug

  48 weeks

Study Arms (1)

Quad FDC

EXPERIMENTAL

FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks

Drug: (FDC) ELV/COBI/FTC/TDF

Interventions

(FDC) ELV/COBI/FTC/TDF DRUG

Antiretroviral treatment

Also known as: STRIBILD

Quad FDC

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Acute HIV Infection (as defined above) within 30 days of study entry.
• Age \>18 years.
• ART-naive (\<14 days of previous antiretroviral treatment. Exceptions are: Post-exposure prophylaxis (PEP) if participant was documented as HIV-negative at least 3 months after completion of PEP.
• Lab values within 30 days prior to study entry:
• Absolute neutrophil count \>500/mm3
• Hemoglobin \> 8.5 g/dL for men and \> 8.0 g/dL for women
• Platelet count \>50,000/mm3
• AST (SGOT)\> .2.5 x ULN
• ALT (SGPT)\> .2.5 x ULN
• Total bilirubin \<2.5 x ULN
• Calculated creatinine clearance (Cockcroft-Gault formula) \> 70mL/min:
• For women of reproductive potential, a negative pregnancy test within 72 hours prior to initiating antiretroviral study medications. Reproductive potential is defined as females who have reached menarche and have not been post-menopausal for at least 24 consecutive months, or have not undergone surgical sterilization.
• Female study participants must use a reliable form of barrier contraception, such as a condom, even if they also use other methods of birth control. All participants must continue to use contraception for 12 weeks after stopping study medications. Acceptable methods of barrier contraception include: condoms (male or female), diaphragm, or cervical cap. These can be used alone or in tandem with hormonal or IUD method.
• Ability and willingness of participant to give written informed consent.

You may not qualify if:

• Women who are pregnant or breast-feeding.
• Women with a positive pregnancy test prior to study drug administration.
• Men who have sex with women, and women of reproductive potential unwilling or unable to use an acceptable, reliable barrier method of contraception for the entire study period and 12 weeks afterwards.
• Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days of study entry (Prednisone 10 mg QD or less is permitted.
• Known allergy/sensitivity to study drugs
• Difficulty swallowing pills
• Inability to communicate effectively with study personnel
• Incarceration; prisoner recruitment and participation are not permitted
• Active drug or alcohol use that, in the opinion of the site investigator, would interfere with participation in the study
• Any active psychiatric illness that, in the opinion of the investigator, could confound the analysis of the neurological examination or neuropsychological test results
• Active brain infection (except for HIV-1), brain neoplasm, space-occupying brain lesion requiring acute or chronic therapy
• Serious illness requiring systemic treatment and/or hospitalization until patient either completes therapy or is clinically stable on therapy for at least 7 days prior to study entry
• Known cardiac conduction disease
• Prior treatment with any other experimental drug within 30 days of initiating study treatment
• Unable to discontinue any current medications that are excluded during study treatment

Sponsors & Collaborators

• Duke University: lead

Study Sites (2)

UNC at Chapel Hill

Chapel Hill, North Carolina, 27514, United States

Location

Duke University Medical Center

Durham, North Carolina, 27705, United States

Location

Related Publications (1)

• Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, McGee KS, Kerkau M, Sebastian J, Fiscus SA, Margolis DM, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011 Apr 24;25(7):941-9. doi: 10.1097/QAD.0b013e3283463c07.

  PMID: 21487250 BACKGROUND

MeSH Terms

Interventions

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Intervention Hierarchy (Ancestors)

Cobicistat; Carbamates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Tenofovir; Organophosphonates; Organophosphorus Compounds; Thiazoles; Sulfur Compounds; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Emtricitabine; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Adenine; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Drug Combinations; Pharmaceutical Preparations

Results Point of Contact

• Title: Mehri McKeller, MD
• Organization: Duke University Medical Center

kara.mcgee@duke.edu

919-668-0242

Study Officials

• Mehri McKellar, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2012
• First Posted: September 27, 2012
• Study Start: September 1, 2012
• Primary Completion: April 1, 2016
• Study Completion: February 1, 2017
• Last Updated: April 12, 2017
• Results First Posted: December 23, 2016

Record last verified: 2017-03

Locations

US (2)